ViiV Healthcare has reported that its two-drug HIV regimen Dovato achieved non-inferior virologic efficacy compared with Gilead Sciences’ three-drug regimen Biktarvy after 48 weeks in treatment-naive adults living with HIV-1. The company-reported results came from VOGUE, an ongoing Phase 3b study described as the first randomised head-to-head comparison of the two once-daily oral regimens in people beginning antiretroviral treatment.
The finding is clinically important because it addresses a question that earlier Dovato studies could not answer directly. Dolutegravir and lamivudine had already accumulated evidence from trials against other three-drug comparators and from studies involving patients switching from established therapy. VOGUE instead places Dovato directly against Biktarvy, one of the most commercially successful and widely used contemporary HIV treatments, in adults who had not previously received antiretroviral therapy.
The results do not establish that Dovato is superior to Biktarvy, and the numerical suppression rate was modestly lower in the Dovato group. The trial nevertheless met its prespecified non-inferiority objective, indicating that the difference remained within the statistical boundary established by the study protocol. That distinction matters. The evidence supports comparable antiviral efficacy at Week 48 within the trial’s statistical framework, not an interchangeable clinical conclusion for every patient or treatment setting.
What did the VOGUE trial reveal about viral suppression with Dovato and Biktarvy?
VOGUE enrolled 509 treatment-naive adults living with HIV-1 across multiple countries. Participants were randomly assigned to receive either Dovato, which combines dolutegravir and lamivudine, or Biktarvy, which combines bictegravir, emtricitabine and tenofovir alafenamide. The study was open-label, meaning participants and investigators knew which regimen had been assigned. Treatment was initiated before baseline resistance-testing results were available, a design feature that may make the study particularly relevant to rapid-start HIV treatment practices.
At Week 48, 89% of participants assigned to Dovato, representing 226 of 254 people, achieved HIV-1 RNA levels below 50 copies per millilitre. The corresponding result for Biktarvy was 92%, or 235 of 255 participants. The adjusted treatment difference was negative three percentage points, with a 95% confidence interval extending from negative eight percentage points to positive two percentage points. ViiV Healthcare reported that this result satisfied the trial’s non-inferiority criterion.
Median time to viral suppression was 4.1 weeks in both treatment groups. ViiV Healthcare also reported that no treatment-emergent resistance was identified in either arm through the disclosed follow-up period. Seven participants in each treatment group discontinued their assigned regimen because they did not achieve or maintain viral suppression.
These results strengthen the argument that a carefully selected two-drug regimen can provide first-line antiviral control without automatically requiring a three-drug combination. However, the three-percentage-point numerical difference should not disappear beneath the non-inferiority label. Clinicians will want to examine the full conference presentation, including the handling of missing data, reasons for treatment discontinuation, protocol deviations and the exact distribution of virologic outcomes.
Why does the inclusion of people with high viral loads matter for interpreting Dovato?
The VOGUE population included a substantial number of participants with markers associated with more clinically challenging initial presentations. At baseline, 47% had HIV-1 RNA levels of at least 100,000 copies per millilitre, while 16% had levels of at least 500,000 copies per millilitre. Sixteen per cent entered the study with CD4-positive T-cell counts below 200 cells per cubic millimetre.
Including these participants gives VOGUE broader relevance than a trial concentrated primarily on people with lower viral loads and relatively preserved immune function. It also supports ViiV Healthcare’s effort to position Dovato as an option across a wider treatment-naive population rather than only among people perceived as having less complex disease.
The initial announcement, however, did not provide complete viral-suppression rates for each high-viral-load or low-CD4 subgroup. It therefore cannot yet establish that the overall non-inferiority result was reproduced with equal precision across every baseline-risk category. The subgroup poster scheduled for AIDS 2026 and the full scientific presentation will be important for understanding whether numerical differences emerged in smaller or clinically vulnerable groups. ViiV Healthcare scheduled the primary VOGUE presentation for July 28, followed by a study-population poster on July 29.
The distinction is particularly relevant because subgroup analyses often have less statistical power than the main trial. A directionally consistent result can be reassuring without necessarily being conclusive. The strength of VOGUE will ultimately depend on whether efficacy remains robust across baseline viral load, CD4 count, demographic characteristics, adherence patterns and geographic settings.
Does using two medicines instead of three create a meaningful clinical advantage?
ViiV Healthcare’s central strategic argument is that people beginning lifelong HIV treatment may benefit from reducing cumulative exposure to antiretroviral medicines when comparable viral control can be maintained. Jean van Wyk, ViiV Healthcare’s chief medical officer, indicated that the number of medicines taken over decades of care remains relevant and said VOGUE adds direct evidence that treatment can begin with fewer antiretroviral agents without sacrificing the trial’s efficacy or resistance outcomes.
That proposition is intuitively attractive, but drug count alone is not a clinical endpoint. A two-drug regimen is not automatically safer, easier to tolerate or more appropriate than a three-drug regimen. Outcomes depend on the specific components, their toxicity profiles, drug interactions, resistance characteristics, comorbidities, pregnancy considerations, organ function and concurrent infections.
The disclosed VOGUE results described the overall safety profiles as comparable and reported no new safety signals. The initial announcement did not provide a detailed breakdown of serious adverse events, treatment-related adverse events, discontinuations for toxicity, renal markers, lipid changes, body-weight outcomes or patient-reported measures. Those data will be needed before the fewer-medicines argument can be translated into a measurable tolerability or quality-of-life advantage.
VOGUE is expected to follow participants for approximately 96 weeks, with assessments that include efficacy, safety, participant-reported outcomes and implementation measures. The longer follow-up could clarify whether small differences emerge in durability, tolerability or adherence after the first year.
Why will hepatitis B status remain a decisive factor when choosing between the regimens?
The comparison between Dovato and Biktarvy cannot be reduced to two drugs against three because the regimens have clinically important differences beyond tablet composition. Dovato contains dolutegravir and lamivudine. Its United States indication covers adults and adolescents aged at least 12 years and weighing at least 25 kilograms who have no antiretroviral treatment history, or eligible virologically suppressed patients replacing an existing regimen, provided there is no known resistance to its components.
Dovato’s prescribing information carries a boxed warning concerning people coinfected with HIV-1 and hepatitis B virus. Lamivudine-resistant hepatitis B variants can emerge when lamivudine is used without adequate additional hepatitis B therapy. ViiV Healthcare’s safety information states that additional treatment for chronic hepatitis B should be considered when Dovato is used in coinfected patients, or an alternative HIV regimen should be selected.
Biktarvy contains emtricitabine and tenofovir alafenamide in addition to bictegravir. These components give the regimen a different role in patients with HIV and hepatitis B coinfection, although Biktarvy also carries a boxed warning because stopping emtricitabine or tenofovir-containing therapy can lead to acute hepatitis B exacerbations. Its label also requires attention to renal function, drug interactions and other patient-specific factors.
Consequently, even convincing VOGUE efficacy data will not make the two regimens universally substitutable. Hepatitis B testing, resistance history, renal status, interacting medicines and treatment continuity remain essential to regimen selection. The trial informs one major part of the decision, antiviral efficacy in treatment-naive HIV-1, but it does not erase label-specific differences.
How could the VOGUE results affect competition between ViiV Healthcare and Gilead Sciences?
Biktarvy is not merely a scientific comparator. It is a commercial anchor for Gilead Sciences. The company reported Biktarvy sales of approximately $3.36 billion during the first quarter of 2026, an increase of 7% from the corresponding period of 2025. Total Gilead Sciences HIV product sales increased 10% to approximately $5 billion during the quarter.
GSK plc, the majority owner of ViiV Healthcare, reported HIV sales of approximately £1.8 billion for the first quarter of 2026, representing growth of 10% at actual exchange rates. The portfolio includes Dovato alongside long-acting products and other established HIV medicines.
VOGUE therefore gives ViiV Healthcare a more direct evidence platform for conversations with clinicians, payers and treatment-guideline committees. Instead of relying mainly on comparisons against older regimens or separate studies, the company can point to randomised results involving the leading three-drug competitor in previously untreated adults.
Commercial displacement will still be difficult. Biktarvy has an extensive evidence base, broad familiarity among prescribers and substantial existing patient use. Gilead Sciences is also developing new HIV regimens with longer dosing intervals. The company and Merck have reported positive Phase 3 results for an investigational once-weekly combination of islatravir and lenacapavir in virologically suppressed patients, while Gilead Sciences has secured Priority Review for a separate bictegravir and lenacapavir combination.
The competitive question is therefore moving beyond whether two daily medicines can match three. Future differentiation may centre on daily versus weekly dosing, oral versus injectable administration, resistance coverage, comorbidity management, treatment simplicity and patient preference. VOGUE strengthens Dovato’s position in the current daily-oral market, but the market itself is continuing to evolve.
Did investors treat the VOGUE announcement as a material stock-market catalyst?
GSK plc shares listed in London rose 2.16% to close at £19.61 on July 27, 2026, although the stock remained about 14% below its 52-week high. Gilead Sciences shares gained 0.94% in the United States to close at $130.52 during the same session. Both movements occurred during a broadly constructive market day, making it inappropriate to attribute either change specifically to the VOGUE announcement.
The restrained interpretation is that VOGUE represents a strategically useful portfolio signal for GSK rather than a stand-alone financial reset. Dovato already has regulatory approval and an established commercial presence, so the study does not remove a fundamental regulatory barrier in the way a first pivotal success might for an investigational drug.
Its value lies in competitive positioning, prescriber confidence and the potential to support continued uptake among treatment-naive patients. Any meaningful financial effect will develop through prescription trends, market share, formulary positioning and the durability of the broader ViiV Healthcare HIV franchise rather than through one day of share-price movement.
What evidence will determine whether VOGUE changes routine first-line HIV care?
The Week 48 result answers the primary efficacy question but leaves several clinically and commercially important questions open. Full safety tables will be needed to determine whether either regimen produced meaningful differences in adverse events, renal outcomes, metabolic markers, weight, treatment discontinuation or patient-reported experience.
Week 96 findings will test whether the suppression rates remain stable and whether resistance continues to be absent with longer exposure. Detailed subgroup outcomes will be particularly important for participants who began treatment with very high viral loads, low CD4 counts or other characteristics that could complicate rapid treatment initiation.
Guideline committees and clinicians will also assess how well the trial population represents routine practice, where hepatitis B coinfection, uncertain resistance history, interacting medicines, inconsistent adherence and delayed laboratory results can influence treatment decisions. Open-label design is unlikely to undermine an objective viral-load endpoint, but it may affect subjective tolerability and participant-reported outcomes.
VOGUE gives ViiV Healthcare the strongest direct evidence yet for presenting Dovato as a credible first-line alternative to Biktarvy. The result validates non-inferior viral suppression at Week 48 with one fewer antiretroviral component, but it does not declare a universal winner. The decisive test will be whether longer follow-up and fuller safety data demonstrate that reducing drug exposure produces advantages that clinicians and patients can measure, not merely a smaller ingredient count on the label.
